Tags

Type your tag names separated by a space and hit enter

How nasopharyngeal pneumococcal carriage evolved during and after a PCV13-to-PCV10 vaccination programme switch in Belgium, 2016 to 2018.
Euro Surveill. 2020 02; 25(5)ES

Abstract

BackgroundThe current carriage study was set up to reinforce surveillance during/after the PCV13-to-PCVC10 switch in Belgium.AimThis observational study monitored carriage of Streptococcus pneumoniae (Sp) serotypes, particularly those no longer covered (3, 6A, 19A), as well as Haemophilus influenzae (Hi), because PCV10 contains the non-typeable Hi protein D.MethodsA total of 2,615 nasopharyngeal swabs from children (6-30 months old) attending day care were collected in three periods over 2016-2018. Children's demographic and clinical characteristics and vaccination status were obtained through a questionnaire. Sp and Hi were identified by culture and PCR. Pneumococcal strains were tested for antimicrobial (non-)susceptibility by disc diffusion and serotyped by Quellung-reaction (Quellung-reaction and PCR for serotypes 3, 6A, 19A).ResultsThe carriage prevalence of Sp (> 75%) remained stable over the successive periods but that of Hi increased (87.4%, 664 Hi-carriers/760 in 2016 vs 93.9%, 895/953 in 2017-2018). The proportion of non-PCV13 vaccine serotypes decreased (94.6%, 438 isolates/463 in 2016 vs 89.7%, 599/668 in 2017-2018) while that of PCV13-non-PCV10 vaccine serotypes (3 + 6A + 19A) increased (0.9%, 4 isolates/463 in 2016 vs 7.8%, 52/668 in 2017-2018), with serotype 19A most frequently identified (87.9%, 58/66 isolates). Non-susceptibility of pneumococci against any of the tested antibiotics was stable over the study period (> 44%).ConclusionsDuring and after the PCV13-to-PCV10 vaccine switch, the proportion of non-PCV13 serotypes decreased, mainly due to a serotype 19A carriage prevalence increase. These results complement invasive pneumococcal disease surveillance data, providing further basis for pneumococcal vaccination programme policy making.

Authors+Show Affiliations

Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.Reference Centre for Pneumococci, University Hospitals Leuven, Leuven, Belgium.Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.Centre for Health Economics Research and Modelling Infectious Diseases, University of Antwerp, Wilrijk, Belgium.Centre for Health Economics Research and Modelling Infectious Diseases, University of Antwerp, Wilrijk, Belgium.Reference Centre for Pneumococci, University Hospitals Leuven, Leuven, Belgium.Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.The members of the NPcarriage Study Group are listed at the end of the article.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32046817

Citation

Wouters, Ine, et al. "How Nasopharyngeal Pneumococcal Carriage Evolved During and After a PCV13-to-PCV10 Vaccination Programme Switch in Belgium, 2016 to 2018." Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, vol. 25, no. 5, 2020.
Wouters I, Desmet S, Van Heirstraeten L, et al. How nasopharyngeal pneumococcal carriage evolved during and after a PCV13-to-PCV10 vaccination programme switch in Belgium, 2016 to 2018. Euro Surveill. 2020;25(5).
Wouters, I., Desmet, S., Van Heirstraeten, L., Herzog, S. A., Beutels, P., Verhaegen, J., Goossens, H., Van Damme, P., Malhotra-Kumar, S., & Theeten, H. (2020). How nasopharyngeal pneumococcal carriage evolved during and after a PCV13-to-PCV10 vaccination programme switch in Belgium, 2016 to 2018. Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, 25(5). https://doi.org/10.2807/1560-7917.ES.2020.25.5.1900303
Wouters I, et al. How Nasopharyngeal Pneumococcal Carriage Evolved During and After a PCV13-to-PCV10 Vaccination Programme Switch in Belgium, 2016 to 2018. Euro Surveill. 2020;25(5) PubMed PMID: 32046817.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - How nasopharyngeal pneumococcal carriage evolved during and after a PCV13-to-PCV10 vaccination programme switch in Belgium, 2016 to 2018. AU - Wouters,Ine, AU - Desmet,Stefanie, AU - Van Heirstraeten,Liesbet, AU - Herzog,Sereina A, AU - Beutels,Philippe, AU - Verhaegen,Jan, AU - Goossens,Herman, AU - Van Damme,Pierre, AU - Malhotra-Kumar,Surbhi, AU - Theeten,Heidi, AU - ,, PY - 2020/2/13/entrez PY - 2020/2/13/pubmed PY - 2020/11/11/medline KW - Children KW - Day-care centres KW - Haemophilus influenzae KW - Nasopharyngeal carriage KW - Pneumococcal conjugate vaccines KW - Streptococcus pneumoniae JF - Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin JO - Euro Surveill VL - 25 IS - 5 N2 - BackgroundThe current carriage study was set up to reinforce surveillance during/after the PCV13-to-PCVC10 switch in Belgium.AimThis observational study monitored carriage of Streptococcus pneumoniae (Sp) serotypes, particularly those no longer covered (3, 6A, 19A), as well as Haemophilus influenzae (Hi), because PCV10 contains the non-typeable Hi protein D.MethodsA total of 2,615 nasopharyngeal swabs from children (6-30 months old) attending day care were collected in three periods over 2016-2018. Children's demographic and clinical characteristics and vaccination status were obtained through a questionnaire. Sp and Hi were identified by culture and PCR. Pneumococcal strains were tested for antimicrobial (non-)susceptibility by disc diffusion and serotyped by Quellung-reaction (Quellung-reaction and PCR for serotypes 3, 6A, 19A).ResultsThe carriage prevalence of Sp (> 75%) remained stable over the successive periods but that of Hi increased (87.4%, 664 Hi-carriers/760 in 2016 vs 93.9%, 895/953 in 2017-2018). The proportion of non-PCV13 vaccine serotypes decreased (94.6%, 438 isolates/463 in 2016 vs 89.7%, 599/668 in 2017-2018) while that of PCV13-non-PCV10 vaccine serotypes (3 + 6A + 19A) increased (0.9%, 4 isolates/463 in 2016 vs 7.8%, 52/668 in 2017-2018), with serotype 19A most frequently identified (87.9%, 58/66 isolates). Non-susceptibility of pneumococci against any of the tested antibiotics was stable over the study period (> 44%).ConclusionsDuring and after the PCV13-to-PCV10 vaccine switch, the proportion of non-PCV13 serotypes decreased, mainly due to a serotype 19A carriage prevalence increase. These results complement invasive pneumococcal disease surveillance data, providing further basis for pneumococcal vaccination programme policy making. SN - 1560-7917 UR - https://www.unboundmedicine.com/medline/citation/32046817/How_nasopharyngeal_pneumococcal_carriage_evolved_during_and_after_a_PCV13_to_PCV10_vaccination_programme_switch_in_Belgium_2016_to_2018_ L2 - http://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.5.1900303 DB - PRIME DP - Unbound Medicine ER -